Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/24/2026

1. JMKE
2. BABA
3. REF
4. NVDA
5. TSLA
6. XPEV
7. GGR
8. CG
9. BA
10. SPY

Go back to Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
Regeneron (NASDAQ: REGN) Delayed: 834.04 --0 (-0%)
Previous Close $834.04    52 Week High $592.36 
Open $834.04    52 Week Low $325.35 
Day High $834.04    P/E 218.91 
Day Low $834.04    EPS $3.81 
Volume 126